Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Boston Scientific completes enrollment of Taxus Element paclitaxel-eluting coronary stent trial

Boston Scientific : 08 October, 2008  (Company News)
Boston Scientific has completed enrollment in the Perseus trial, which is designed to evaluate the company's third-generation Taxus Element paclitaxel-eluting coronary stent.
The Perseus clinical programme has enrolled nearly 1,500 patients at 100 USA and international centres since July 2007, and will compare the Taxus Element Stent to the prior-generation Taxus Express2 Stent marketed in the United States since 2004. The company plans to develop additional versions of the Element platform, including next generations of a bare-metal Stent and an everolimus-eluting Promus Element Stent system.

'We are pleased to reach this important milestone in the development of our third-generation drug-eluting stent, at a time when most companies are still introducing their first-generation stents in the US,' said Keith Dawkins, MD, senior vice president and associate chief medical officer for Boston Scientific. 'Boston Scientific is the only company to offer interventionalists a choice between two different drugs in a DES platform.

The advanced Platinum Chromium Alloy and new balloon Catheter offered in the Element system will further strengthen our deep portfolio of coronary Stent technologies.'

The Element Stent platform features the proprietary Platinum Chromium Alloy, designed specifically for stents. The alloy, coupled with an innovative new Stent architecture, is designed to enable thinner struts for increased flexibility, a lower profile, and improved radial strength, recoil, and radiopacity. In addition, the Taxus Element Stent System incorporates new balloon technology, intended to improve on Boston Scientific's market-leading Maverick Balloon Catheter platform.

'The new alloy and Stent design of Taxus Element provides improved deliverability and visibility, even in patients with complex and challenging anatomy,' said Dean J Kereiakes, MD, medical director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati and the principal investigator for the trials. 'I am very enthusiastic about the potential the Taxus Element Stent offers me to treat a broader range of patients.'

The Taxus Perseus clinical programme will evaluate the efficacy and safety of the Taxus Element Stent in two studies.

The first study, Taxus Perseus Workhorse (A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the Taxus Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions), will evaluate the safety and efficacy of the Taxus Element Stent compared to Boston Scientific's first generation drug-eluting stent, the Taxus Express Stent. This 3:1 randomised study will evaluate 1,264 patients from 94 sites in the USA, Australia, New Zealand and Singapore with ‘workhorse’ lesions from 2.75 to 4.0 mm in diameter. The primary endpoint of the workhorse study is target lesion failure (TLF) at 12 months, and its secondary endpoint is in-segment percent diameter stenosis at nine months.

A second parallel study named the Taxus Perseus Small Vessel study will compare the Taxus Element Stent to a historic control (Taxus V de novo bare-metal Express Coronary Stent System). The study will include 224 patients from 35 US sites with lesions from 2.25 up to 2.75mm.

The primary endpoint of the small vessel study is in-stent late loss at nine months, and its secondary endpoint is TLF at 12 months.

Boston Scientific is currently seeking CE Mark approval in European markets, which is anticipated in 2009.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   Â© 2012
Netgains Logo